Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liothyronine I 131
- Development stage
- Unknown
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous (typical For Radiotherapeutics), Possibly Oral (if Formulated As Such; Not Standard)
01
Overview
Liothyronine I 131 is a radioconjugate consisting of the synthetic thyroid hormone liothyronine (T3) labeled with radioactive iodine isotope Iodine 131. It combines the metabolic and cellular regulatory effects of liothyronine—a key hormone in growth, development, and metabolism—with the radiotherapeutic properties of iodine 131. This compound is primarily investigated for use in radiotherapy for thyroid cancers and has also been studied in clinical trials for congenital heart defects such as tricuspid atresia. The radioactive component allows targeted destruction of thyroid tissue or cancer cells that uptake thyroid hormones[5][7][2].
- Brand names
- Tri-ThyrotopeTriomet-131Triomet131Triomet 131
- Other names
- Liothyronine I 131 [USAN]L-Tyrosine, o-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-, labeled with iodine-131(2S)-2-amino-3-(4-(4-hydroxy-3-(131I)iodophenoxy)-3,5-di(131I)iodophenyl)propanoic acid
02
Targets
THRB (Thyroid hormone receptor beta)THRA (Thyroid hormone receptor alpha)
Beyond the preview
Go deeper on Liothyronine I 131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liothyronine I 131.